1 of 1
Story summary
- The FDA plans a pilot program offering bonuses to drug reviewers who finish work early, announced by FDA chief Dr. Marty Makary.
- The FDA is expediting drug approvals, including one-month reviews for certain drugs and relaxed trial requirements.
- Concerns have been raised about potential pressure to rush safety steps.
- The agency's chief scientist Dr. Vinay Prasad has rejected some applications, emphasizing the need for more evidence.
